临床与分子数据预测类风湿关节炎DMARD优化治疗中的 flare:一项随机对照开放标签非劣效试验
OPTIBIO试验在西班牙5家医院纳入195例持续缓解且稳定使用bDMARD的RA患者,1:1随机分为标准治疗组或剂量减量组。12个月内flare发生率优化组22.7%、对照组17.2%,风险差-5.5%(95%CI -16.8%至5.7%;P=0.33),未能证明非劣效但安全性相似。研究构建了预测flare和持续缓解的模型,加入分子标志物后AUC分别提升至0.91和0.88。
要点
- bDMARD剂量优化在flare率上未达到非劣效于标准治疗,但不良事件无显著差异。
- 基于3v-DAS28-CRP、疼痛VAS、骨侵蚀、收缩压和血红蛋白的flare预测模型AUC为0.84。
- 加入分子生物标志物后flare和持续缓解预测模型AUC分别提升至0.91和0.88。
核心结论
- bDMARD剂量优化在flare率上未证明非劣效于标准治疗,但安全性相似;预测模型可能帮助筛选患者以安全实施该策略。
研究设计与样本
- OPTIBIO试验(EudraCT 2012-004482-40)为IV期、随机、开放标签、非劣效研究,在西班牙5家医院开展。
- 195例持续缓解且稳定使用bDMARD的RA患者按1:1随机分为标准治疗组(99例)和剂量减量优化组(96例)。
- 主要结局为比较基线至12个月关节flare比例,按意向性分析进行非劣效检验,并识别flare和持续缓解的预测因素。
主要发现
- flare预测模型(AUC 0.84)纳入3v-DAS28-CRP、疼痛VAS、骨侵蚀、收缩压和血红蛋白。
- 持续缓解预测模型(AUC 0.77)纳入3v-DAS28-CRP、年龄和类风湿因子。
- 加入分子生物标志物后,flare和持续缓解模型的AUC分别提升至0.91和0.88。
- 不良事件方面未观察到显著差异。
关键数值与推荐
- 非劣效分析采用意向性分析原则,比较基线至12个月关节flare比例,风险差-5.5%(95%CI -16.8%至5.7%;P=0.33)。
- flare预测模型AUC为0.84,持续缓解预测模型AUC为0.77,加入分子标志物后分别升至0.91和0.88。
临床怎么用
- 对持续缓解的RA患者优化bDMARD剂量时,需警惕flare风险,该策略未证明非劣效于标准治疗。
- 可参考基于临床变量和分子标志物的预测模型筛选适合剂量优化的患者,以降低flare风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to identify robust predictive markers which may help personalize tapering protocols, minimizing flare risk while optimizing long-term disease management in RA patients. METHODS: The OPTIBIO trial (EudraCT 2012-004482-40) was a phase IV, randomized, open-label, non-inferiority study conducted in five hospitals in Spain. RA patients in sustained remission on stable bDMARD therapy were randomized 1:1 to standard care or dose reduction. The primary outcome was to compare the proportion of joint flare between baseline and 12 months by a non-inferiority analysis analysed by the intention-to-treat principle and to identify predictors for flare and sustained remission. RESULTS: A total of 195 patients were randomized: 99 to the control group and 96 to the optimization group. Thirty-nine flares occurred (optimization: 22.7%, control: 17.2%), with a risk difference of -5.5% (95% CI: -16.8% to 5.7%; P = 0.33). Two predictive models were developed: one for flares (AUC: 0.84) including 3v-DAS28-CRP, VAS pain, erosions, systolic blood pressure and haemoglobin, and another for sustained remission (AUC: 0.77) including 3v-DAS28-CRP, age and rheumatoid factor. Adding molecular biomarkers improved AUCs to 0.91 and 0.88, respectively. No significant differences in adverse events were observed. CONCLUSION: bDMARD dose optimization was not non-inferior to standard therapy on the flare rate but demonstrated similar safety. Predictive models for remission and flares were developed, which may help select patients to ensure safe implementation of this strategy, highlighting the need for personalized treatment. TRIAL REGISTRATION: www.clinicaltrialsregister.eu; EudraCT 2012-004482-40.
引用
- Blanco FJ, Galindo L, Acasuso B, et al. Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial. Rheumatology (Oxford). 2026. PMID: 41578952. doi:10.1093/rheumatology/keag050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。